Obagi Medical Launches Lip Therapy Protocol Targeting Rejuvenation and Protection
Event summary
- Obagi Medical, part of Waldencast plc (NASDAQ: WALD), launched a two-step Lip Therapy protocol on February 3, 2026.
- The protocol includes the AHA + PHA Smoothing Micro-Peel ($55) and Soothe & Protect Lip Treatment SPF 30 ($40).
- Consumer testing showed immediate smoothing effects with continued improvements in hydration and fine lines within two weeks.
- Obagi Medical is the fastest-growing professional skincare brand in the U.S. as of 2024.
The big picture
Obagi Medical’s launch of a targeted lip therapy protocol underscores its strategy of extending medical-grade skincare solutions to delicate facial areas. As part of Waldencast plc, Obagi benefits from operational scale and brand agility, reinforcing its position as the fastest-growing professional skincare brand in the U.S. The move aligns with broader industry trends toward specialized, science-backed beauty products that address specific skin concerns.
What we're watching
- Market Differentiation
- Whether Obagi Medical can sustain its growth trajectory by leveraging targeted innovations like the Lip Therapy protocol.
- Consumer Adoption
- The pace at which consumers adopt this specialized lip care regimen, particularly post-professional treatments.
- Competitive Positioning
- How Obagi Medical’s clinical validation and dermatologist-tested claims will position it against competitors in the professional skincare space.
Related topics